A review of picotamide in the reduction of cardiovascular events in diabetic patients

Andrea Celestini
Francesco Violi

IV Divisione di Clinica Medica, Department of Experimental Medicine and Pathology, University of Rome “La Sapienza,” Italy

Abstract: Picotamide is an antiplatelet drug with a dual inhibitory action. Thus, picotamide inhibits both thromboxane A2 (TxA2) receptors and TxA2 synthase and, at variance with aspirin, does not interfere with endothelial prostacyclin (PGI2) production. Two large randomized trials have been performed to assess the clinical efficacy of picotamide in patients at risk of atherothrombosis. The ADEP study compared peripheral artery disease (PAD) patients randomized to picotamide or placebo. This study did not show a significant reduction of cardiovascular events by picotamide but a subgroup analysis showed its potential usefulness in patients with diabetes. To investigate this issue further, the DAVID study recently enrolled diabetic patients with PAD randomized to picotamide versus aspirin; the results showed a significant reduction of overall mortality in the picotamide group. Moreover long-term picotamide treatment in diabetes promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques. These data suggest that picotamide may represent an interesting drug to be further investigated in future trials in the atherothrombotic setting.

Keywords: picotamide, aspirin, diabetes, cardiovascular events, peripheral artery disease

Introduction

Picotamide, a derivative of methoxy-isophtalic acid, is an antiplatelet drug that inhibits both thromboxane A2 (TxA2) receptors and TxA2 synthase. As concentrations of the molecule needed to inhibit both pathways are almost equivalent (Modesti et al 1994), picotamide may exert a dual pharmacological action in vivo and be potentially useful in various clinical settings characterized by atherosclerotic disease. Picotamide has been investigated in two large clinical trials in patients suffering from cardiovascular events, ie, in patients with peripheral artery disease (PAD) (Balsano and Violi 1993) and in patients with diabetes (Neri Serneri et al 2004). This review will focus on the results of these two trials and on the future perspective of picotamide in the setting of cardiovascular disease.

Pharmacology

Upon platelet activation, arachidonic acid is released from platelet membrane by phospholipase A2 (PLA2)-mediated degradation of membrane phospholipids and is converted to prostaglandin endoperoxides, as prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2), via cyclooxygenase-1 (COX-1) activation. PGH2 is then converted by TxA2 synthase to TxA2. Furthermore, PGH2 participates in cycles of amplification signals for platelet activation by recruitment of other platelets through interaction with the same receptors of TxA2 (Parise et al 1984; FitzGerald 1991).

TxA2 has detrimental effects on the arterial tone by virtue of its vasoconstrictor property, an effect that is counteracted by endothelial molecules, such as nitric oxide and prostacyclin (PGI2), a cyclo-oxygenase-derived substance.
Aspirin is the most widely used antiplatelet drug to prevent cardiovascular events in patients with acute or chronic cardiovascular diseases (Antithrombotic Trialists’ Collaboration 2002). Aspirin irreversibly acetylates COX-1, thereby preventing TxA2 in platelets and PGI2 in the endothelium. Although endothelial production of PG12 is inhibited only in part by aspirin (Caughey et al 2001), since the 1980s a number of drugs has been developed to interfere selectively with TxA2 activity, without inhibiting endothelial PG12 production (Landolfi et al 1988). Among these drugs picotamide attracted the attention of researchers for its ability to inhibit both TxA2 platelet synthase and platelet TxA2 receptors and, in turn, platelet aggregation. In particular, Violi et al (1988) showed that picotamide at micromolar concentrations inhibited platelet aggregation induced by various agonists, such as ADP, arachidonic acid, and collagen. Furthermore the reduction of platelet aggregation was directly related to the inhibition of TxA2 production. Unlike aspirin, picotamide was not able to reduce the release of PG12 by endothelium. Taken together these results demonstrated that picotamide reduced platelet function by inhibiting TxA2 production without affecting cyclo-oxygenase activity. These data were confirmed by the in vivo study, which showed a consistent reduction of platelet aggregation and TxA2 production in platelets from eight healthy volunteers taking picotamide 1200 mg/die (Violi et al 1988). Moreover Gresele et al (1989) showed that picotamide, apart from reducing the synthesis of TxA2, enhanced the formation of PGE2 in platelets and favored the formation of PG12 by aspirinated endothelial cells.

The evidence that picotamide almost completely inhibits platelet aggregation induced by the TxA2 analogous U46619 suggested that this drug also has an inhibitory effect on TxA2 receptors (Berrettini et al 1990). In this regard, an in vitro study showed that picotamide displaced a selective radioligand of TxA2 receptor from platelets, so indicating that it directly inhibits this receptor (Modesti et al 1989). Other pharmacological studies demonstrated that picotamide binding to thromboxane A2 receptors is initially reversible and becomes progressively non-displaceable (Modesti et al 1991, 1994).

The reduction of circulating platelet-derived TxA2 levels induced by picotamide not only inhibits platelet aggregation, but also has important consequences for the inflammatory processes of atherosclerotic plaque. TxA2 has an important role in regulating vascular tone, as it induced endothelin-1 (ET-1) in both endothelium and smooth muscle cells (Chua et al 1996). As a consequence, the reduction of TxA2 platelet formation induced by picotamide administration decreases vessel tone by reducing the circulating levels of endotelin-1 (Saitta et al 1998). Moreover picotamide reduces smooth muscle cell proliferation as TxA2 is a mythogenic stimulus: in vitro studies with picotamide demonstrated that it inhibits DNA synthesis of smooth muscle cells incubated with U46619 (a TxA2 analog) alone and also with other mythogenic molecules such as EGF or PDGF (Ratti et al 1998). Finally, it should be mentioned that in vitro as well as in vivo studies documented an antiplatelet and antivasoconstrictor property of picotamide that is unrelated to inhibition of TxA2 formation, such as inhibition of serotonin-induced platelet aggregation (Vezza et al 1997).

Platelet activation and aspirin in diabetes

Diabetes is a clinical setting characterized by enhanced platelet activation that depends in part on increased platelet production of thromboxane A2. In fact, Davì et al (1990) showed that urinary thromboxane B2 (TxB2), a stable metabolite of TxA2, was significantly higher in patients with type 2 diabetes than in controls. Moreover, tight diabetic control with insulin therapy reduced urinary 11-dehydrothromboxane B2 by almost 50%, while aspirin therapy reduced this urinary metabolite by 80%. Recovery of impaired excretion of such molecules occurred after an aspirin wash-out of 10 days, suggesting the platelet origin of thromboxane A2.

Aspirin has been used in patients with diabetes to prevent cardiovascular complications, but the results are disappointing because only a slightly reduction in clinical outcomes has been observed compared with patients affected by other cardiovascular risk factors (Antithrombotic Trialists’ Collaboration 2002). The reason why diabetic patients are less sensitive to aspirin than non-diabetic ones is unclear. An enhanced turnover of platelets has been observed in diabetic patients, a phenomenon that could limit the antiplatelet effect of aspirin. However, more data are necessary to support such a hypothesis (Csiszar et al 2002; Di Minno and Violi 2004; Gresele and Migliacci 2004).

A chronic inflammatory state is often associated with diabetes and may be responsible for platelet activation via oxidative stress-mediated formation of isoprostanes (Patrono and FitzGerald 1997). Thus, these molecules are products of non-cyclooxygenase oxidative modifications of arachidonic acid due to oxidative stress-mediated modification of membrane phospholipids or circulating LDLs, and are characterized by potent vasoconstrictor and pro-aggregatory
Platelet activation and aspirin in peripheral arterial disease

Platelet activation as assessed by urinary excretion of TxB2 has been studied in patients with PAD and matched controls (Davi et al. 1997). This study demonstrated enhanced values of urinary TxB2 in PAD patients compared with control. Such differences, however, seemed to be attributable essentially to the coexistence of risk factors for atherosclerotic disease such as hypercholesterolemia, diabetes, or smoking habit. Thus, in PAD patients without such risk factors, urinary excretion of TxB2 was similar to that in controls, suggesting that the risk factors rather than atherosclerotic disease per se are responsible for enhanced production of TxB2.

Despite these data suggesting a role for COX-1 in the pathophysiology of PAD, the clinical efficacy of aspirin in this clinical setting is uncertain. Prospective studies with adequate sample size have never been performed. Data on the effects of aspirin in preventing cardiovascular disease stem essentially from meta-analysis, which have not provided definite findings on its potential efficacy (WAVE Investigators 2006). Therefore further studies with adequate sample size should be performed to investigate the clinical efficacy of aspirin in preventing cardiovascular disease.

Clinical studies

Since the 1970s, prospective studies have shown a strong association between cardiovascular events and type 1 or type 2 diabetes mellitus (Garcia et al 1974; Panzram 1987). Moreover in recent decades the beneficial effects of aspirin and other antiplatelet drugs against myocardial infarction, stroke, and other vascular events have been well documented (Antithrombotic Trialist’s Collaboration 2002). However, aspirin treatment seems to be less useful in diabetic patients compared with patients with other risk factors in primary or secondary prevention of cardiovascular complications. In this regard a recent meta-analysis analysed 4961 subjects among 9 trials and showed only a 7% odds reduction of vascular complications in diabetic patients treated with aspirin versus placebo. Although this reduction hardly reached statistical significance, it is consistently less when compared with the proportional reduction over 195 studies analyzed by the meta-analysis (22% versus 7%) (Antithrombotic Trialist’s Collaboration 2002).

As reported above, evidence for any benefits of aspirin treatment in patients with PAD is insufficient (WAVE Investigators 2006). Thus, in contrast to other authorities (Clagett et al 2004), the Food and Drug Administration expert panel did not provide any indication of aspirin treatment for patients with PAD (Food and Drug Administration 1998). This strongly suggests the need for developing new antplatelet drugs potentially useful in diabetes and PAD.

The first large randomized trial (ADEP trial) on picotamide investigated its clinical usefulness in patients with PAD (Balsano and Violi 1993). For this study 2304 patients were consecutively enrolled, allocated to either placebo or picotamide (300 mg bid), and followed for 18 months. Endpoints of the study were major events (ie, cardiovascular death, myocardial infarction, stroke, or amputation) and minor events (unstable angina, transient ischemic attack, hypertension, renal failure, deterioration of PAD). The “intention to treat analysis” showed a risk reduction (18.9%) in the combined endpoints, major plus minor events, in the picotamide group compared with the controls, which, however, did not reach statistical significance; conversely, “on treatment analysis” showed a higher and statistically significant reduction (22.8%) in the same endpoints. Side-effects such as bleeding were almost identical in the two groups. As the authors suggested, the lack of any beneficial effects of picotamide against major events could have been related to the low occurrence of these events during the follow-up; this phenomenon may be related to a bias in patient selection, which excluded high-risk patients.

The capacity of picotamide to prevent vascular complications was, however, magnified when claudicant patients affected by diabetes were taken into account. Thus, a sub-study of the ADEP trial retrospectively analyzed 438 diabetic patients and observed a risk reduction of 45.2% of combined major and minor events in those treated with picotamide compared with those treated with placebo (Milani et al 1996). On the basis of this post-hoc analysis a new randomized trial (the DAVID trial) was specifically designed for diabetic patients with PAD (Neri Serneri et al 2004). Thus, 1209 patients were enrolled and randomly assigned to picotamide (600 mg bid) or aspirin (320 mg/day) and followed for 2 years. The primary endpoint was the overall mortality and the secondary one was the combined incidence.
of death and major cardiovascular events. Mortality was significantly lower in picotamide-treated patients than in those treated with aspirin, showing a relative risk of reduction of 45%; furthermore the incidence of gastrointestinal bleeding was much lower in the picotamide group than in the aspirin group. The secondary endpoint did not show any significant difference between two populations, showing only a non-significant trend in favor of patients taking picotamide (Tables 1 and 2). As pointed out by the authors, a possible bias relative to the high proportion of patients (about 20% in each group) who discontinued the trial because of non-fatal events may have underestimated the real incidence of the secondary endpoints; moreover it is possible that the sample size of the study was insufficient to detect any difference in these endpoints between the two groups (Tables 1 and 2). Comparison of the results achieved by the ADEP and DAVID trials also raises the question as to whether the differences seen are dependent on the fact that TxA2 production is more relevant for atherosclerotic progression in PAD patients with diabetes compared with PAD without diabetes, or whether the different dosage of picotamide (600 mg vs 1200 mg in the ADEP and DAVID respectively) has a different impact on clinical outcome. Further studies are therefore necessary to explore the relationship between picotamide dosage and TxA2 inhibition in vivo.

In conclusion, despite the interesting findings relative to the reduction of overall mortality and the better safety of picotamide compared with aspirin, other clinical trials are necessary in order to clarify the real clinical benefit of picotamide for ischemic non-fatal events in PAD patients with diabetes.

The beneficial effects of long-term picotamide in diabetic patients are also corroborated by its capacity in reducing microalbuminuria and in inhibiting growth of carotid plaques.

Thirty type 2 diabetic, normotensive patients, all characterized by microalbuminuria at rest, were randomized to picotamide 300 mg/day or placebo for 1 year. Results showed a reduction of microalbuminuria at rest and after exercise without significant changes in metabolic control in the picotamide-treated patients compared with control subjects. Moreover, a linear correlation was found between urinary thromboxane excretion and microalbuminuria after stress-test (Giustina et al 1998). These findings suggest an interesting relationship between thromboxane formation and vascular complication of type 2 diabetes. Thus, the fact that picotamide is more effective in reducing microalbuminuria induced by stress-test than at rest suggests that the vasoconstrictor properties of TxA2 may be responsible for its physiopathological action on glomerular activity.

The effects on plaque progression are also supported by a 2-year prospective study that demonstrated a reduction of carotid plaque evolution in diabetic patients, affected by non-stenotic and asymptomatic carotid atherosclerosis. In

| Table 1 Baseline characteristics and side-effects of both ADEP and DAVID trials |
|-----------------|-----------------|-----------------|-----------------|
|                 | Picotamide 300 mg bid | Placebo 600 mg bid | Picotamide 600 mg bid | Aspirin 320 mg od |
| **Dosage**      |                  |                  |                  |
| **Clinical characteristics** |                  |                  |                  |
| n = 1150        |                  | n = 1154         | n = 603          | n = 606           |
| Age             | 63.4 ± 7.3       | 62.9 ± 7.4       | 63.8 ± 7.2       | 64.6 ± 7.3        |
| Diabetes        | 20%              | 18%              | 100%             | 100%              |
| PAD             | 100%             | 100%             | 100%             | 100%              |
| Smoke           | 39.6%            | 37.1%            | 30.5%            | 28.4%             |
| Hypertension    | 34.5%            | 37.5%            | 58.2%            | 55.6%             |
| Dyslipidemia    | 36.5%            | 35.8%            | 38%              | 38.4%             |
| Previous stroke | 1.4%             | 1.7%             | 10.4%            | 10.2%             |
| Coronary heart disease | 15%             | 12.7%            | 19.4%            | 19%                |
| **Side-effects** |                  |                  |                  |
| Gastro-intestinal | 11.1%           | 12%              | 10.9%            | 18.3%             |
| Total           | 14.3%            | 13.5%            | 25.6%            | 33.9%             |

**Abbreviations:** bid, twice a day; od, once a day; PAD, peripheral artery disease.
Table 2 Duration of follow-up, endpoints and statistically relevant results of both ADEP and DAVID trials

|                  | ADEP study | DAVID study|
|------------------|------------|-------------|
| Follow-up        | 18 months  | 24 months   |
| Primary endpoints| Major events: death, MI, stroke, amputation | Overall mortality |
| Secondary endpoints| Minor events: UA, TIA, hypertension, renal failure, deterioration of PAD | Stroke, MI, amputation, other death |
| Statistical significance | Major plus minor events (“on treatment analysis”) | Overall mortality |
| Percentage of event in statistically relevant endpoints | picotamide 10.1% placebo 13% | picotamide 3% aspirin 5.5% |

Abbreviations: MI, myocardial infarction; PAD, peripheral artery disease; TIA, transient ischemic attack; UA, unstable angina.

extension, 50 type II normotensive diabetic patients with asymptomatic mild or moderate non-stenotic (<50%) carotid atherosclerotic plaque were randomly given picotamide 300 mg/day or placebo; after 2 years, lesion numbers and percentage stenosis in the picotamide group were significantly lower than in the placebo group (Cocozza et al 1995).

Conclusion

The data so far reported on the effect of picotamide in patients at risk of atherothrombosis are of particular interest overall because the clinical efficacy of picotamide has emerged in patients with diabetes, who seem to be less sensitive to the effect of other antiplatelet drugs such as aspirin. Although the number of patients included in trials with picotamide was not limited, trial results are still insufficient to provide definite conclusions on its clinical efficacy. Therefore the results of the above-reported trials should represent a useful background to further test the hypothesis that an antiplatelet drug with a dual mechanism of action such as picotamide may be beneficial in preventing the cardiovascular events in patients with atherothrombosis. In this context it is interesting to mention a recent experimental study in which a combination of drugs inhibiting COX-1 and TxA2 receptor antagonist has been investigated in an animal model of atherosclerosis (Cyrus et al 2006). The study showed that such a combination possesses a greater anti-atherosclerotic property than the single drug, so providing further support for the potentially clinical usefulness of drugs with dual COX-1 and TxA2 receptor inhibition. The DAVID study suggests that in patients with PAD and diabetes, antiplatelet drugs with similar pharmacological characteristics should be investigated. The study should be prospective and include more than 1500 patients (the sample size primarily considered by the DAVID committee as number of patients necessary to detect a significant difference between picotamide and aspirin), and should obviously compare picotamide versus aspirin in a follow-up of 2 years. Such a study could provide more definite data on the clinical efficacy of picotamide in this clinical setting and potentially open new avenues in an atherosclerotic subsetting where the clinical efficacy of aspirin is still debated.

References

Antithrombotic Trialist’s Collaboration. 2002. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ, 324:71–86.

Balsano F, Violi F. 1993. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation, 87:1563–9.

Berrettini M, De Cunto M, Parise P, et al. 1990. “In vitro” and “ex vivo” effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets. Eur J Clin Pharmacol, 39:495–500.

Caughey GE, Cleland LG, Penglia PS, et al. 2001. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol, 167:2831–8.

Chua CC, Hamdy RC, Chua BH. 1996. Regulation of endothelin-1 production by a thromboxane A2 mimetic in rat heart smooth muscle cells. Biochim Biophys Acta, 1313:1–5.

Clagett GP, Sobel M, Jackson MR, Lip GYH, et al. 2004. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest, 26:609S–26S.

Cocozza M, Picano T, Oliviero U, et al. 1995. Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution. A two-year, double-blind, placebo-controlled study in diabetic patients. Stroke, 597–601.

Csiszár A, Stef G, Pacher P, et al. 2002. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandin, Leukot Essent Fatty Acid, 66:557–8.

Cyrus T, Yao J, Ding T, et al. 2006. Thromboxane receptor blockade improves the anti-atherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood, Dec 7. (Epub ahead of print).

Davi G, Gresele P, Violi F, et al. 1997. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation, 96:69–75.

Di Minno G, Violi F, 2004. Aspirin resistance and diabetic angiopathy: back to the future. Thromb Res, 113:97–9.

FitzGerald GA. 1991. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol, 68:11B–158.

Food and Drug Administration. 1998. Internal analgesic, antipyretic, and antirheumatic drug products for OTC human use: final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Fed Regist, 63:56802–19.

Garcia ML, McNamara PM, Gordon T, et al. 1974. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes, 23:105–11.

Giustina A, Perini F, Desenzani P, et al. 1998. Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes, 47:423–30.

Vascular Health and Risk Management 2007:3(1)
Celestini and Violi

Gresele P, Migliacci R. 2004. Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath? Eur Heart J, 25:1769–71.

Gresele P, Deckmyn H, Arnout J, et al. 1989. Characterization of N, N’-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thromb Haemost, 6:479–84.

Landolfi R, Castellana MA, De Cristofaro R. 1988. Effect of picotamide on prostacyclin production by human endothelial cells. Thromb Haemost, 60:529.

Milani M, Longoni A, Maderna M. 1996. Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br J Clin Pharmacol, 42:782–5.

Modesti PA, Cecioni I, Colella A, et al. 1994. Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist. Br J Pharmacol, 112:81–6.

Modesti PA, Colella A, Abbate R, et al. 1989. Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide. Eur J Pharmacol, 4;169:85–93.

Modesti PA, Colella A, Cecioni I, et al. 1991. Acute reduction of TxA2 platelet binding sites after in vivo administration of a TxA2 receptor inhibitor. Br J Clin Pharmacol, 31:439–43.

Neri Serneri GG, Coccheri S, Marubini E, et al. 2004. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J, 25:1845–52.

Panzram G. 1987. Mortality and survival in type 2 diabetes (non insulin dependent diabetes). Diabetologia, 30:123–31.

Parise LV, Venton DL, Le Breton GC. 1984. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. J Pharmacol Exp Ther, 228:240–4.

Patrono C, FitzGerald GA. 1997. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol, 17:2309–15.

Ratti S, Quarato P, Casagrande C, et al. 1998. Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes. Eur J Pharmacol, 355:77–83.

Saitta A, Sardo A, Bonaiuto M, et al. 1998. Effects of picotamide on release of endothelin-1, thromboxane and prostacycline after treadmill stress in patients with peripheral artery disease. Angiology, 49:879–90.

Vezza R, Spina D, Tallarida RJ, et al. 1997. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism. Thromb Haemost, 78:1385–91.

Violi F, Ghiselli A, Iuliano L, et al. 1988. Inhibition by picotamide of thromboxane production in vitro and ex vivo. Eur J Clin Pharmacol, 33:599–602.

WAVE Investigators. 2006. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am Heart J, 151:1–9.